Admedus Release: Announcement To The Australian Stock Exchange
30th January 2015
Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000
Dear Sir/Madam,
Re: Appendix 4C - Quarterly Report
Please refer to the ‘Appendix 4C’ attached for details for the period ended 31st December 2014 for the Group.
• Revenue for the group continues to grow to $4.8M for the half year
•Significant progress with the immunotherapy programmes
•CardioCel® being used in Europe, Asia, North America and Australia
During the past quarter, the group had total sales of $2.5M, up 23% from the corresponding previous period and up 10% from the previous quarter this financial year. The company has $9.6 million in cash. CardioCel® sales for the first half of the year were around $1M. Admedus is also expecting to receive R&D tax rebates this financial year.
The number of centres using CardioCel® in both Europe and the US continues to rise. Currently, CardioCel® is used in 26 centres in Europe and 23 centres in the US and the Group has continued to expand the market for CardioCel® in the second quarter with Health Canada granting a marketing licence and the Company achieving Special Access approval for its use in Singapore.
Admedus will continue to seek additional approvals in other jurisdictions as part of the global launch of CardioCel®.
In collaboration with Professor Ian Frazer and his team, the Company also made significant progress with the immunotherapy vaccine programmes. During this period, the Company announced ethics approval for the HSV-2 Phase II clinical study, which is being initiated, with interim results anticipated towards the end of 2015.
In addition, the Company also announced the latest HPV pre-clinical data which showed compelling results for the HPV therapeutic vaccine. The results showed in the TC-1 model 100% survival and over 87% tumour clearance. Having now successfully completed a number of pre-clinical studies with extremely positive results, the team is working to progress the HPV programme into clinical studies.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000
Dear Sir/Madam,
Re: Appendix 4C - Quarterly Report
Please refer to the ‘Appendix 4C’ attached for details for the period ended 31st December 2014 for the Group.
• Revenue for the group continues to grow to $4.8M for the half year
•Significant progress with the immunotherapy programmes
•CardioCel® being used in Europe, Asia, North America and Australia
During the past quarter, the group had total sales of $2.5M, up 23% from the corresponding previous period and up 10% from the previous quarter this financial year. The company has $9.6 million in cash. CardioCel® sales for the first half of the year were around $1M. Admedus is also expecting to receive R&D tax rebates this financial year.
The number of centres using CardioCel® in both Europe and the US continues to rise. Currently, CardioCel® is used in 26 centres in Europe and 23 centres in the US and the Group has continued to expand the market for CardioCel® in the second quarter with Health Canada granting a marketing licence and the Company achieving Special Access approval for its use in Singapore.
Admedus will continue to seek additional approvals in other jurisdictions as part of the global launch of CardioCel®.
In collaboration with Professor Ian Frazer and his team, the Company also made significant progress with the immunotherapy vaccine programmes. During this period, the Company announced ethics approval for the HSV-2 Phase II clinical study, which is being initiated, with interim results anticipated towards the end of 2015.
In addition, the Company also announced the latest HPV pre-clinical data which showed compelling results for the HPV therapeutic vaccine. The results showed in the TC-1 model 100% survival and over 87% tumour clearance. Having now successfully completed a number of pre-clinical studies with extremely positive results, the team is working to progress the HPV programme into clinical studies.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.